

Rubber industry

Butadiene or styrene or butadiene and styrene or else?

K Straif, R Baan, V Coglianò

Commentary on the paper by Sathiakumar *et al*
(*Occup Environ Med*, December 2005)*

In the December 2005 issue of this journal, Sathiakumar and colleagues¹ report on the extended follow up of the University of Alabama cohort in the styrene–butadiene–rubber industry. The update confirms the increased risk of haemato-lymphopoietic malignancies in work areas with high exposure to butadiene and styrene. This study is both potentially informative and at the centre of controversies regarding the evidence for the human carcinogenicity of butadiene and styrene.

In 1999, an IARC Working Group concluded that butadiene is “probably carcinogenic to humans” (Group 2A) on the basis of “limited evidence” of carcinogenicity in humans and “sufficient evidence” in experimental animals.² A case-control study nested in the University of Alabama cohort³ showed a consistent excess of leukaemia and a statistically significant dose–response relationship with cumulative exposure to 1,3-butadiene, which remained after adjustment for exposure to styrene. Studies among workers in butadiene production reported an excess of lymphohaematopoietic cancers.

In 2002 a separate IARC Working Group concluded that styrene is “possibly carcinogenic to humans” (Group 2B) on the basis of “limited evidence” in epidemiological studies of cancer in humans as well as in experimental animals.⁴ Studies of glass fibre reinforced plastics workers were considered to be the most informative with regard to the carcinogenicity of styrene, but findings from the styrene–butadiene–rubber industry also contributed to the evidence: an excess of leukaemia mortality increased with cumulative exposure to styrene in analyses that only considered this exposure; however, in analyses that adjusted for exposure to 1,3-butadiene, the exposure–response relationship became non-monotonic.

Thus, there was agreement in different IARC Working Groups regarding an increased risk for haemato-lymphopoietic malignancies in work areas with high exposures to butadiene and styrene. However, the Working Groups struggled

with the interpretation and consistency of these findings across studies. Challenges included: (1) the high correlation between butadiene and styrene exposures, which made it difficult to disentangle the effects of the two; and (2) the aetiologically most sensible categorisation of the haemato-lymphopoietic malignancies into leukaemias and lymphomas, given that this information is derived from death certificates coded according to the International Classification of Diseases in effect at the time of death.

Both IARC evaluations have been criticised^{5,6} and other committees came to different conclusions regarding the carcinogenicity of butadiene and styrene. In 1998, the German MAK commission⁷ categorised butadiene as a “substance that causes cancer in man” (category 1). In the 9th edition, in 2000, the NTP Report on Carcinogens raised the classification of butadiene to “known to be human carcinogen”,⁸ and in 2002 the US EPA characterised butadiene as “carcinogenic to humans”.⁹ In 2002, the NTP Report on Carcinogens first listed styrene oxide, the reactive metabolite of styrene, “as reasonably anticipated to be a human carcinogen”, while styrene is not classified. Styrene oxide is listed in IARC’s Group 2A. The German MAK characterised styrene as “carcinogen with no significant contribution to human cancer risk”, provided that the MAK and BAT values are observed (category 5).

There was also agreement that occupational exposure to these agents needs to be drastically reduced. The American Conference of Governmental Industrial Hygienists (ACGIH) (which is not a governmental agency) classified butadiene as “suspected human carcinogen” (A2), and styrene was considered as “not classifiable as a human carcinogen” (A4).¹⁰ Nevertheless, over the last

*Sathiakumar N, Graff J, Macaluso M, *et al*. An updated study of mortality among North American synthetic rubber industry workers. *Occup Environ Med* 2005;**62**:822–9.

decades, the ACGIH recommended a substantial reduction of time weighted average threshold limit values (TLV-TWA), from 5000 to 2 ppm and from 400 to 20 ppm, for butadiene and styrene respectively. There was a large reduction for butadiene, from 1000 to 10 ppm, that accompanied the A2 designation in 1986.

With the extended follow up, the overall number of haemato-lymphopoietic malignancies increased from 115 to 162, with increased risks primarily observed for leukaemia among hourly paid workers (SMR 123, 95% CI 94 to 157). Risks were concentrated among workers with 10 or more years of employment and 20–29 years after hire (SMR 258, 95% CI 156 to 403), and in workers employed in polymerisation (SMR 204, 95% CI 121 to 322), coagulation (SMR 231, 95% CI 111 to 425), maintenance labour (SMR 203, 95% CI 114 to 335), and laboratories (SMR 326, 95% CI 178 to 546).¹ Thus, the study will allow for enhanced exposure specific analyses. Yet, the cancer hazard identification for butadiene and styrene has been controversial, and one may safely assume that these controversies will last. So far, this study only adds to the concern.

What’s next? Due to the inherent problems of this study there is also a need to advance updates of other epidemiological studies potentially informative with regard to the carcinogenicity of butadiene or styrene. Further, molecular epidemiological studies are ongoing¹¹ and mechanistic studies may also contribute to the overall evidence. Some countries, by setting more stringent occupational limit values for butadiene and styrene, have taken steps towards primary prevention of butadiene and styrene related occupational cancers. Finally, one should not forget that butadiene is also an important environmental pollutant^{8,12} with much larger populations being exposed for more than 40 hours a week, including potentially more susceptible populations such as young children.

Occup Environ Med 2006;**63**:157–158.
doi: 10.1136/oem.2005.023986

Authors’ affiliations

K Straif, R Baan, V Coglianò, International Agency for Research on Cancer, Lyon, France

Correspondence to: Dr K Straif, International Agency for Research on Cancer, 150, cours Albert Thomas, F-69372 Lyon cedex 08, France; strai@iarc.fr

Competing interests: none

The opinions expressed here are those of the authors and do not necessarily represent those of IARC

REFERENCES

- 1 **Sathiakumar N**, Graff J, Macaluso M, et al. An updated study of mortality among North American synthetic rubber industry workers. *Occup Environ Med* 2005;**62**:822–9.
- 2 **IARC**. *Monographs on the evaluation of carcinogenic risk of chemicals to humans. Volume 71. Re-evaluation of some organic chemicals, hydrazine and hydrogen peroxide (part 1)*. Lyon: IARC, 1999.
- 3 **Macaluso M**, Larson R, Delzell E, et al. Leukemia and cumulative exposure to butadiene, styrene and benzene among workers in the synthetic rubber industry. *Toxicology* 1996;**13**:190–202.
- 4 **IARC**. *Monographs on the evaluation of carcinogenic risk of chemicals to humans. Volume 82. Some traditional herbal medicines, some mycotoxins, naphthalene and styrene*. Lyon: IARC, 2002.
- 5 **Tomatis L**. The IARC monographs program: changing attitudes towards public health. *Int J Occup Environ Health* 2002;**8**:144–52.
- 6 **Huff J**. IARC monographs, industry influence, and upgrading, downgrading, and under-grading chemicals: a personal point of view. *Int J Occup Environ Health* 2002;**8**:249–70 (erratum in *Int J Occup Environ Health* 2003;**9**:84).
- 7 **DFG (Deutsche Forschungsgemeinschaft)**. *List of MAK and BAT values 2005. Commission for the investigation of health hazards of chemical compounds in the work area. Report no. 41*. Weinheim: Wiley-VCH Verlag, 2005.
- 8 **NTP**. *Report on carcinogens*, 11th edn. Research Triangle Park, NC: US Department of Health and Human Services, Public Health Service, National Toxicology Program, National Institute of Environmental Health Sciences, 2004.
- 9 **US EPA**. *Health assessment document for 1,3-butadiene*. Washington, DC: Office of Research and Development, 2002 (EPA/600/P-98/001).
- 10 **American Conference of Governmental Industrial Hygienists**. *Documentation of the threshold limit values and biological exposure indices*. Cincinnati, OH: ACGIH, 2004.
- 11 **Albertini RJ**, Sram RJ, Vacek PM, et al. Biomarkers in Czech workers exposed to 1,3-butadiene: a transitional epidemiologic study. *Res Rep Health Eff Inst* 2003;**116**:1–141.
- 12 **Vandenberg JJ**. Hazardous air pollutants: approaches and challenges in identifying assessment priorities. In: Cogliano VJ, Straif K, Samet J, eds. *Air pollution and cancer*. Lyon: IARC (in press).

Clinical Evidence—Call for contributors

Clinical Evidence is a regularly updated evidence-based journal available worldwide both as a paper version and on the internet. *Clinical Evidence* needs to recruit a number of new contributors. Contributors are healthcare professionals or epidemiologists with experience in evidence-based medicine and the ability to write in a concise and structured way.

Areas for which we are currently seeking contributors:

- Pregnancy and childbirth
- Endocrine disorders
- Palliative care
- Tropical diseases

We are also looking for contributors for existing topics. For full details on what these topics are please visit www.clinicalevidence.com/cweb/contribute/index.jsp

However, we are always looking for others, so do not let this list discourage you.

Being a contributor involves:

- Selecting from a validated, screened search (performed by in-house Information Specialists) epidemiologically sound studies for inclusion.
- Documenting your decisions about which studies to include on an inclusion and exclusion form, which we keep on file.
- Writing the text to a highly structured template (about 1500-3000 words), using evidence from the final studies chosen, within 8-10 weeks of receiving the literature search.
- Working with *Clinical Evidence* editors to ensure that the final text meets epidemiological and style standards.
- Updating the text every 12 months using any new, sound evidence that becomes available. The *Clinical Evidence* in-house team will conduct the searches for contributors; your task is simply to filter out high quality studies and incorporate them in the existing text.

If you would like to become a contributor for *Clinical Evidence* or require more information about what this involves please send your contact details and a copy of your CV, clearly stating the clinical area you are interested in, to CECommissioning@bmjgroup.com.

Call for peer reviewers

Clinical Evidence also needs to recruit a number of new peer reviewers specifically with an interest in the clinical areas stated above, and also others related to general practice. Peer reviewers are healthcare professionals or epidemiologists with experience in evidence-based medicine. As a peer reviewer you would be asked for your views on the clinical relevance, validity, and accessibility of specific topics within the journal, and their usefulness to the intended audience (international generalists and healthcare professionals, possibly with limited statistical knowledge). Topics are usually 1500-3000 words in length and we would ask you to review between 2-5 topics per year. The peer review process takes place throughout the year, and out turnaround time for each review is ideally 10-14 days.

If you are interested in becoming a peer reviewer for *Clinical Evidence*, please complete the peer review questionnaire at www.clinicalevidence.com/cweb/contribute/peerreviewer.jsp